Literature DB >> 10948159

Transcutaneous immunization with bacterial ADP-ribosylating exotoxins, subunits, and unrelated adjuvants.

T Scharton-Kersten1, J m Yu, R Vassell, D O'Hagan, C R Alving, G M Glenn.   

Abstract

We have recently described a needle-free method of vaccination, transcutaneous immunization, consisting of the topical application of vaccine antigens to intact skin. While most proteins themselves are poor immunogens on the skin, we have shown that the addition of cholera toxin (CT), a mucosal adjuvant, results in cellular and humoral immune responses to the adjuvant and coadministered antigens. The present study explores the breadth of adjuvants that have activity on the skin, using diphtheria toxoid (DTx) and tetanus toxoid as model antigens. Heat-labile enterotoxin (LT) displayed adjuvant properties similar to those of CT when used on the skin and induced protective immune responses against tetanus toxin challenge when applied topically at doses as low as 1 microg. Interestingly, enterotoxin derivatives LTR192G, LTK63, and LTR72 and the recombinant CT B subunit also exhibited adjuvant properties on the skin. Consistent with the latter finding, non-ADP-ribosylating exotoxins, including an oligonucleotide DNA sequence, as well as several cytokines (interleukin-1beta [IL-1beta] fragment, IL-2, IL-12, and tumor necrosis factor alpha) and lipopolysaccharide also elicited detectable anti-DTx immunoglobulin G titers in the immunized mice. These results indicate that enhancement of the immune response to topical immunization is not restricted to CT or the ADP-ribosylating exotoxins as adjuvants. This study also reinforces earlier findings that addition of an adjuvant is important for the induction of robust immune responses to vaccine antigens delivered by topical application.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10948159      PMCID: PMC101793          DOI: 10.1128/IAI.68.9.5306-5313.2000

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  31 in total

1.  Principles of transcutaneous immunization using cholera toxin as an adjuvant.

Authors:  T Scharton-Kersten; G M Glenn; R Vassell; J Yu; D Walwender; C R Alving
Journal:  Vaccine       Date:  1999-10-01       Impact factor: 3.641

2.  CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen.

Authors:  H L Davis; R Weeratna; T J Waldschmidt; L Tygrett; J Schorr; A M Krieg; R Weeranta
Journal:  J Immunol       Date:  1998-01-15       Impact factor: 5.422

3.  Skin immunization made possible by cholera toxin.

Authors:  G M Glenn; M Rao; G R Matyas; C R Alving
Journal:  Nature       Date:  1998-02-26       Impact factor: 49.962

Review 4.  Vaccine developments.

Authors:  M A Liu
Journal:  Nat Med       Date:  1998-05       Impact factor: 53.440

Review 5.  The mechanism of cholera toxin adjuvanticity.

Authors:  N Lycke
Journal:  Res Immunol       Date:  1997 Oct-Dec

6.  Transcutaneous immunization with bacterial ADP-ribosylating exotoxins as antigens and adjuvants.

Authors:  G M Glenn; T Scharton-Kersten; R Vassell; G R Matyas; C R Alving
Journal:  Infect Immun       Date:  1999-03       Impact factor: 3.441

7.  Transcutaneous immunization with cholera toxin protects mice against lethal mucosal toxin challenge.

Authors:  G M Glenn; T Scharton-Kersten; R Vassell; C P Mallett; T L Hale; C R Alving
Journal:  J Immunol       Date:  1998-10-01       Impact factor: 5.422

8.  Genetically detoxified mutants of heat-labile toxin from Escherichia coli are able to act as oral adjuvants.

Authors:  G Douce; V Giannelli; M Pizza; D Lewis; P Everest; R Rappuoli; G Dougan
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

9.  Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12- and IFN-gamma-dependent mechanisms.

Authors:  P S Walker; T Scharton-Kersten; A M Krieg; L Love-Homan; E D Rowton; M C Udey; J C Vogel
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-08       Impact factor: 11.205

10.  Mucosal immunization with HIV-1 peptide vaccine induces mucosal and systemic cytotoxic T lymphocytes and protective immunity in mice against intrarectal recombinant HIV-vaccinia challenge.

Authors:  I M Belyakov; M A Derby; J D Ahlers; B L Kelsall; P Earl; B Moss; W Strober; J A Berzofsky
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-17       Impact factor: 11.205

View more
  31 in total

1.  Immunization onto bare skin with synthetic peptides: immunomodulation with a CpG-containing oligodeoxynucleotide and effective priming of influenza virus-specific CD4+ T cells.

Authors:  Anne-Sophie Beignon; Jean-Paul Briand; Sylviane Muller; Charalambos D Partidos
Journal:  Immunology       Date:  2002-02       Impact factor: 7.397

Review 2.  The development and use of vaccine adjuvants.

Authors:  Robert Edelman
Journal:  Mol Biotechnol       Date:  2002-06       Impact factor: 2.695

3.  Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells.

Authors:  Igor M Belyakov; Scott A Hammond; Jeffrey D Ahlers; Gregory M Glenn; Jay A Berzofsky
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

4.  Transcutaneous immunization with cytotoxic T-cell peptide epitopes provides effective antitumor immunity in mice.

Authors:  Tsuyoshi Itoh; Esteban Celis
Journal:  J Immunother       Date:  2005 Sep-Oct       Impact factor: 4.456

Review 5.  Topical vaccination: the skin as a unique portal to adaptive immune responses.

Authors:  Chun-Ming Huang
Journal:  Semin Immunopathol       Date:  2007-04       Impact factor: 9.623

6.  Transcutaneous immunization with cross-reacting material CRM(197) of diphtheria toxin boosts functional antibody levels in mice primed parenterally with adsorbed diphtheria toxoid vaccine.

Authors:  Paul Stickings; Marisa Peyre; Laura Coombes; Sylviane Muller; Rino Rappuoli; Giuseppe Del Giudice; Charalambos D Partidos; Dorothea Sesardic
Journal:  Infect Immun       Date:  2008-01-28       Impact factor: 3.441

7.  Transcutaneous immunization with a synthetic hexasaccharide-protein conjugate induces anti-Vibrio cholerae lipopolysaccharide responses in mice.

Authors:  Julianne E Rollenhagen; Anuj Kalsy; Rina Saksena; Alaullah Sheikh; Mohammad Murshid Alam; Firdausi Qadri; Stephen B Calderwood; Pavol Kovác; Edward T Ryan
Journal:  Vaccine       Date:  2009-06-27       Impact factor: 3.641

8.  Generation of antigen-specific immunity following systemic immunization with DNA vaccine encoding CCL25 chemokine immunoadjuvant.

Authors:  Noshin Kathuria; Kimberly A Kraynyak; Diane Carnathan; Michael Betts; David B Weiner; Michele A Kutzler
Journal:  Hum Vaccin Immunother       Date:  2012-11-01       Impact factor: 3.452

9.  Protection against aerosolized Yersinia pestis challenge following homologous and heterologous prime-boost with recombinant plague antigens.

Authors:  Audrey Glynn; Chad J Roy; Bradford S Powell; Jeffrey J Adamovicz; Lucy C Freytag; John D Clements
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

10.  Adjuvanted influenza vaccine administered intradermally elicits robust long-term immune responses that confer protection from lethal challenge.

Authors:  Maria del P Martin; Shaguna Seth; Dimitrios G Koutsonanos; Joshy Jacob; Richard W Compans; Ioanna Skountzou
Journal:  PLoS One       Date:  2010-05-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.